394 related articles for article (PubMed ID: 27732970)
1. Advances in sarcoma diagnostics and treatment.
Dancsok AR; Asleh-Aburaya K; Nielsen TO
Oncotarget; 2017 Jan; 8(4):7068-7093. PubMed ID: 27732970
[TBL] [Abstract][Full Text] [Related]
2. Advances in sarcoma gene mutations and therapeutic targets.
Gao P; Seebacher NA; Hornicek F; Guo Z; Duan Z
Cancer Treat Rev; 2018 Jan; 62():98-109. PubMed ID: 29190505
[TBL] [Abstract][Full Text] [Related]
3. Targeting sarcomas: therapeutic targets and their rational.
Ordóñez JL; Martins AS; Osuna D; Madoz-Gúrpide J; de Alava E
Semin Diagn Pathol; 2008 Nov; 25(4):304-16. PubMed ID: 19013896
[TBL] [Abstract][Full Text] [Related]
4. Advances and controversies in the management of soft tissue sarcomas.
Demetri GD; Blay JY; Casali PG
Future Oncol; 2017 Jan; 13(1s):3-11. PubMed ID: 27918199
[TBL] [Abstract][Full Text] [Related]
5. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
[TBL] [Abstract][Full Text] [Related]
6. Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.
Pishas KI; Neuhaus SJ; Clayer MT; Schreiber AW; Lawrence DM; Perugini M; Whitfield RJ; Farshid G; Manavis J; Chryssidis S; Mayo BJ; Haycox RC; Ho K; Brown MP; D'Andrea RJ; Evdokiou A; Thomas DM; Desai J; Callen DF; Neilsen PM
Cancer Res; 2014 Feb; 74(3):921-31. PubMed ID: 24336067
[TBL] [Abstract][Full Text] [Related]
7. The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope.
Groisberg R; Roszik J; Conley A; Patel SR; Subbiah V
Curr Oncol Rep; 2017 Oct; 19(12):78. PubMed ID: 29030741
[TBL] [Abstract][Full Text] [Related]
8. New Strategies in Sarcoma: Linking Genomic and Immunotherapy Approaches to Molecular Subtype.
Lim J; Poulin NM; Nielsen TO
Clin Cancer Res; 2015 Nov; 21(21):4753-9. PubMed ID: 26330427
[TBL] [Abstract][Full Text] [Related]
9. Molecular profiling of sarcomas: new vistas for precision medicine.
Al-Zaid T; Wang WL; Somaiah N; Lazar AJ
Virchows Arch; 2017 Aug; 471(2):243-255. PubMed ID: 28664413
[TBL] [Abstract][Full Text] [Related]
10. Role of genetic and molecular profiling in sarcomas.
Norberg SM; Movva S
Curr Treat Options Oncol; 2015 May; 16(5):24. PubMed ID: 25939540
[TBL] [Abstract][Full Text] [Related]
11. Newer therapeutic strategies for soft-tissue sarcomas.
Bourcier K; Italiano A
Pharmacol Ther; 2018 Aug; 188():118-123. PubMed ID: 29481809
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas.
Shor AC; Agresta SV; D'Amato GZ; Sondak VK
Cancer Control; 2008 Jan; 15(1):47-54. PubMed ID: 18094660
[TBL] [Abstract][Full Text] [Related]
13. Advances of systemic treatment for adult soft-tissue sarcoma.
Liu W; Jiang Q; Zhou Y
Chin Clin Oncol; 2018 Aug; 7(4):42. PubMed ID: 30173532
[TBL] [Abstract][Full Text] [Related]
14. Targeted Chemotherapy in Bone and Soft-Tissue Sarcoma.
Harwood JL; Alexander JH; Mayerson JL; Scharschmidt TJ
Orthop Clin North Am; 2015 Oct; 46(4):587-608. PubMed ID: 26410647
[TBL] [Abstract][Full Text] [Related]
15. Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma?
Ratan R; Patel SR
Curr Treat Options Oncol; 2017 Jun; 18(6):34. PubMed ID: 28534249
[TBL] [Abstract][Full Text] [Related]
16. Emerging therapeutic targets for synovial sarcoma.
Palmerini E; Paioli A; Ferrari S
Expert Rev Anticancer Ther; 2014 Jul; 14(7):791-806. PubMed ID: 24661286
[TBL] [Abstract][Full Text] [Related]
17. Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas.
Sethi TK; Keedy VL
Curr Treat Options Oncol; 2016 Feb; 17(2):11. PubMed ID: 26931561
[TBL] [Abstract][Full Text] [Related]
18. Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomas.
Koseła-Paterczyk H; Rutkowski P
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1107-1116. PubMed ID: 28988501
[TBL] [Abstract][Full Text] [Related]
19. Targeted agents for sarcoma: is individualized therapy possible in such a diverse tumor type?
Riedel RF
Semin Oncol; 2011 Oct; 38 Suppl 3():S30-42. PubMed ID: 22055970
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 clinical trials for sarcomas: the cutting edge.
Subbiah V; Kurzrock R
Curr Opin Oncol; 2011 Jul; 23(4):352-60. PubMed ID: 21519259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
